UCB announces U.S. FDA approval for ZILBRYSQ® (zilucoplan) autoinjector self-administration for adults living with generalized myasthenia gravis
ZILBRYSQ is the first and only macrocyclic peptide C5 inhibitor approved as a self-administered once-daily, subcutaneous autoinjector for adults living with generalized myasthenia gravis (gMG) in the U.S.¹ ZILBRYSQ now offers two self-administration options for adults living with gMG who...
Covered in this story
What has happened since
- United Community Banks Inc is up 5.2% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $UCB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on United Community Banks Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.